CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies

Infection and Immunity

Volumn 68, Issue 3, 2000, Pages 1450-1456

  Chu, Rose S ^a   Mccool, Tera ^a,b   Greenspan, Neil S ^a   Schreiber, John R ^a,b   Harding, Clifford V ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; OLIGODEOXYNUCLEOTIDE; PNEUMOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; DINUCLEOSIDE PHOSPHATES; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0033969664     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.3.1450-1456.2000     Document Type: Article

References (33)

1. Adams, W. G., K. A. Deaver, S. L. Cochi, B. D. Plikavtis, E. R. Zell, C. V. Broome, and J. D. Wenger. 1993. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 269:221-226.
2. 197. Infect. Immun. 39:233-238.
3. Askew, D., R. Chu, A. Krieg, and C. V. Harding. 1999. CpG DNA and LPS cause dendritic cell (DC) maturation with distinct effects on nascent and recycling MHC-II antigen processing. FASEB J. 13:A279.
4. Briles, D. E., J. L. Claflin, K. Schroer, and C. Forman. 1981. Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature 294:88-90.
5. Chu, R., O. S. Targoni, A. M. Krieg, P. V. Lehmann, and C. V. Harding. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1623-1631.
6. Cooper, L. J., J. C. Schimenti, D. D. Glass, and N. S. Greenspan. 1991. H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate. J. Immunol. 146:2659-2663.
7. Davis, H. L., R. Weeranta, T. J. Wald Schmidt, L. Tygrett, J. Schorr, and A. M. Krieg. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:870-876.
8. Ey, P. L., G. J. Russell-Jones, and C. R. Jenkin. 1980. Isotypes of mouse IgG-1. Evidence for "non-complement-fixing" IgG1 antibodies and characterization of their capacity to interfere with IgG2 sensitization of target red blood cells for lysis by complement. Mol. Immunol. 17:699-710.
9. Greenspan, N. S., and L. J. N. Cooper. 1992. Intermolecular cooperativity: a clue to why mice have IgG3? Immunol. Today 13:164-168.
10. Greenspan, N. S., W. J. Monafo, and J. M. Davie. 1987. Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: enhancing and inhibiting effects of anti-GAC, anti-isotypic, and anti-idiotypic antibodies. J. Immunol. 138:285-292.
11. Jakob, T., P. S. Walker, A. M. Krieg, M. C. Udey, and J. C. Vogel. 1998. Activation of cutaneous dendritic cells by CpG-containmg oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol. 161:3042-3049.
12. Käyhty, H., and J. Eskola. 1996. New vaccines for the prevention of pneumococcal infections. Emerg. Infect. Dis. 2:289-298.
13. Kovarik, J., P. Bozzotti, L. Love-Homan, M. Pihlgren, H. L. Davis, P. H. Lambert, A. M. Krieg, and C. A. Siegrist. 1999. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol. 162:1611-1617.
14. Krieg, A. M., A.-K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B cell activation. Nature 374:546-549.
15. Lee, C.-J, 1987. Bacterial capsular polysaccharides - biochemistry, immunity and vaccine. Mol. Immunol. 24:1005-1019.
16. Lipford, G. B., M. Bauer, C. Blank, R. Reiter, H. Wagner, and K. Heeg. 1997. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27:2340-2344.
17. McCool, T. L., C. V. Harding, N. S. Greenspan, and J. R. Schreiber. 1999. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. Infect. Immun. 67:4862-4869.
18. Mond, J. J., A. Lees, and C. M. Snapper. 1995. T cell-independent antigens type 2. Annu. Rev. Immunol. 13:655-692.
19. Rennels, M. B., K. M. Edwards, H. L. Keyserling, K. S. Reisinger, D. A. Hogerman, D. V. Madore, I. Chang, P. R. Paradiso, F. J. Malinoski, and A. Kimura. 1998. Safety and immunogenicity of heplavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101:604-611.
20. Roman, M., E. Martin-Orozco, J. S. Goodman, M. D. Nguyen, Y. Sato, A. Ronaghy, R. S. Kornbluth, D. D. Richman, D. A. Carson, and E. Raz. 1997. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:849-854.
21. Schneerson, R., O. Barrera, A. Sutton, and J. B. Robbins. 1980. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:361-376.
22. Schreiber, J. R., L. J. N. Cooper, S. Diehn, P. A. Dahlhauser, M. F. Tosi, D. D. Glass, M. Patawaran, and N. S. Greenspan. 1993. Variable region-identical monoclonal antibodies of different IgG subclass directed to Pseudomonas aeruginosa lipopolysaccharide O-specific side chain function differently. J. Infect. Dis. 167:221-226.
23. 197 conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. 18:757-763.
24. Snapper, C. M., and J. J. Mond. 1993. Towards a comprehensive view of immunoglobulin class switching. Immunol. Today 14:15-17.
25. Sparwasser, T., E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart, and H. Wagner. 1998. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28:2045-2054.
26. Stacey, K. J., M. J. Sweet, and D. A. Hume. 1996. Macrophages ingest and are activated by bacterial DNA. J. Immunol. 157:2116-2122.
27. Sun, S., H. Kishimoto, and J. Sprent. 1998. DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J. Exp. Med. 187:1145-1150.
28. Threadgill, D. S., L. L. McCormick, T. L. McCool, N. S. Greenspan, and J. R Schreiber. 1998. Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. Vaccine 16:76-82.
29. Tygrett, L., S. Wiechert, X. Li, K. Takahashi, A. Krieg, and T. Waldschmidt. 1999. Capacity of CpG ODN to enhance TNP-Ficol1 responses in mice. FASEB J. 13:A990.
30. Uchida, T., A. M. Pappenheimer, Jr., and A. A. Harper. 1972. Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins. Science 175:901-903.
31. Unkeless, J. C., E. Scigliano, and V. H. Freedman. 1988. Structure and function of human and murine receptors for IgG. Annu. Rev. Immunol. 6:251-281.
32. Vernacchio, L., E. J. Neufeld, K. MacDonald, S. Kurth, S. Murakami, C. Hohne, M. King, and D. Molrine. 1998. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J. Pediatr. 133: 275-278.
33. Yamamoto, S., T. Yamamoto, S. Shimada, E. Kuramoto, O. Yano, T. Kataoka, and T. Tokunaga. 1992. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol. Immunol. 36:983-997.